Education
About Us
Working with TipRanks
Follow Us
Vicarious Surgical (RBOT)
NYSE:RBOT
Top Page
Vicarious Surgical
(NYSE:RBOT)
38Underperform
Positive Factors
Financial Performance
RBOT continues to manage its cash position responsibly, with cash management remaining a key priority ahead of key milestones for its robotic platform.
Market Outlook
The new price target of $13 reflects a positive outlook, increasing from the previous target of $10, based on future sales estimates and a discount rate.
Product Development
RBOT is taking positive steps toward treating its first clinical patient.
Negative Factors
Development Delays
Development milestones and timelines were shifted back 3 to 6 months due to supplier dynamics which have limited key parts within the Vicarious System.
Financial Needs
The company will need to either reduce cash burn or find some sources of non-dilutive financing.
Leadership Challenges
The CFO departure is seen as another challenge for RBOT to handle on its path towards gaining clearance.
Vicarious Surgical (RBOT) vs. S&P 500 (SPY)
Market Cap
$36.59M
Dividend YieldN/A
Average Volume (3M)37.35K
Price to Earnings (P/E)―
Beta (1Y)3.14
Revenue GrowthN/A
EPS Growth-1455.58%
CountryUS
Employees123
SectorHealthcare
Sector Strength71
IndustryMedical - Devices
Share Statistics
EPS (TTM)-7.94
Shares Outstanding5,276,612
10 Day Avg. Volume22,397
30 Day Avg. Volume37,348
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.75Price Target Upside74.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Vicarious Surgical Business Overview & Revenue Model
Company DescriptionVicarious Surgical (RBOT) is a medical technology company that specializes in developing innovative robotic systems designed to enhance minimally invasive surgery. The company's core product is its advanced robotic platform, which integrates proprietary human-like surgical robots with 3D visualization and AI-driven insights to improve surgical precision and outcomes. Vicarious Surgical aims to revolutionize the field of surgery by providing surgeons with enhanced capabilities, improved ergonomics, and reduced procedure times.
How the Company Makes MoneyVicarious Surgical makes money primarily through the sale and leasing of its robotic surgical systems to hospitals and surgical centers. The company may also generate revenue through service contracts and maintenance agreements, ensuring the optimal functionality of its robotic platforms. Additionally, Vicarious Surgical could engage in strategic partnerships with healthcare providers and institutions to expand the adoption of its technology. These partnerships may involve collaborative research, co-development of surgical techniques, and training programs for surgeons. Furthermore, as the company's technology advances, it may explore revenue opportunities through software licensing, offering AI-driven analytics and insights as a service to enhance surgical performance and patient outcomes.
Vicarious Surgical Financial Statement Overview
Summary
Vicarious Surgical is in its early developmental phase, characterized by zero revenue and significant operating losses. The balance sheet remains stable with low leverage, but the cash flows highlight operational cash burn, necessitating ongoing financing. Strategic focus on product development and future revenue generation will be crucial for financial improvement.Income Statement
Vicarious Surgical has reported zero revenue consistently, indicating a pre-revenue stage company. This lack of revenue growth severely impacts the ability to assess profitability metrics like gross and net profit margins, which remain negative due to high operating losses.10
Very Negative
Balance Sheet
The balance sheet reflects a moderate leverage position with a debt-to-equity ratio of 0.30 in 2024, highlighting a manageable level of debt. However, declining equity due to persistent losses could pose future risks. The positive equity ratio of 68.95% suggests some stability in financial structure despite challenges.40
Negative
Cash Flow
The company demonstrates negative free cash flow, indicating cash outflows exceed operating inflows, which is typical for a development-stage firm. The negative operating cash flow to net income ratio shows operational challenges, though cash reserves have been bolstered through financing activities.20
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -1.85M | -1.94M | -316.00K | 0.00 | EBIT |
| -66.56M | -80.67M | -80.08M | -38.57M | -12.98M | EBITDA |
| -66.56M | -69.19M | 7.30M | -34.80M | -161.18K | Net Income Common Stockholders |
| -63.22M | -71.07M | 89.16M | -7.04M | -12.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 49.10M | 98.18M | 116.21M | 173.51M | 16.87M | Total Assets |
| 67.72M | 119.86M | 140.29M | 181.69M | 17.79M | Total Debt |
| 13.79M | 14.83M | 15.69M | 1.34M | 110.00K | Net Debt |
| 4.05M | -37.99M | -100.52M | -172.17M | -16.76M | Total Liabilities |
| 21.02M | 21.89M | 29.25M | 98.95M | 935.00K | Stockholders Equity |
| 46.70M | 97.97M | 111.05M | 82.74M | 16.85M |
| Cash Flow | Free Cash Flow | |||
| -50.14M | -63.98M | -66.56M | -34.59M | -12.16M | Operating Cash Flow |
| -49.96M | -62.30M | -61.21M | -33.30M | -12.04M | Investing Cash Flow |
| 6.86M | -45.78M | -5.35M | -1.29M | 13.20M | Financing Cash Flow |
| 8.00K | 44.70M | 9.14M | 192.16M | 13.52M |
Vicarious Surgical Technical Analysis
Negative
6.17
Price Trends
11.50
Negative
11.96
Negative
9.41
Negative
Market Momentum
-1.39
Positive
26.67
Positive
2.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Negative. The current price of 6.17 is below the 20-day moving average (MA) of 8.50, below the 50-day MA of 11.50, and below the 200-day MA of 9.41, indicating a bearish trend. The MACD of -1.39 indicates Positive momentum. The RSI at 26.67 is Positive, neither overbought nor oversold. The STOCH value of 2.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBOT.
Vicarious Surgical Risk Analysis
Vicarious Surgical disclosed 73 risk factors in its most recent earnings report. Vicarious Surgical reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vicarious Surgical Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $181.97B | 79.19 | 15.62% | ― | 17.24% | 27.76% | |
69 Neutral | $11.61B | 97.46 | 2.52% | ― | 60.62% | -35.88% | |
59 Neutral | $154.76M | ― | -144.19% | ― | 0.55% | -8.47% | |
49 Neutral | $6.85B | 0.81 | -52.76% | 2.50% | 19.89% | 1.27% | |
46 Neutral | $80.39M | ― | -51.63% | ― | 11.26% | -14.21% | |
41 Neutral | $1.81M | ― | -496.27% | ― | -18.55% | -15.21% | |
38 Underperform | $36.59M | ― | -87.40% | ― | ― | -1455.58% |
* Healthcare Sector Average
Performance Comparison
RBOT
Vicarious Surgical
6.17
-2.61
-29.73%
EDAP
EDAP TMS
2.15
-5.41
-71.56%
ISRG
Intuitive Surgical
491.84
96.97
24.56%
STXS
Stereotaxis
1.80
-0.78
-30.23%
GMED
Globus Medical
72.55
19.42
36.55%
VERO
Venus Concept
2.75
-5.06
-64.79%
Vicarious Surgical Earnings Call Summary
Earnings Call Date: Mar 17, 2025 | % Change Since: -35.93% | Next Earnings Date: May 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments and challenges. While the company made significant strides in system integration, partnership expansions, and cost management, they also faced supply chain issues that have delayed clinical trials. The sentiment is balanced with strong achievements countered by notable delays.Highlights
Successful Completion of Version 1.0 System Integration
The company successfully completed the integration of its Version 1.0 system, demonstrating functionality and performance in a cadaveric preclinical setting, marking a significant step forward in bringing their robotic surgery platform to market.
Expansion of Hospital System Partnerships
Vicarious Surgical announced agreements with several major academic health institutions such as LSU Health New Orleans, Temple Health, and University of Illinois Health, which will aid in developing medical education and training protocols.
Reduced Operating Expenses
Total operating expenses for full year 2024 were reduced by 17% year-over-year, with R&D expenses down from $47.6 million in 2023 to $40.2 million in 2024.
Strong Cash Management
The company reported a cash burn rate of $49 million, achieving a favorable variance from the original guidance of $50 million, ending the year with approximately $49 million in cash, cash equivalents, and short-term investments.
Lowlights
Supply Chain Disruptions
The company faced material procurement challenges with key suppliers, causing delays in component deliveries and impacting the manufacturing schedule. This has pushed the first clinical patient treatments closer to the year-end.
Delayed Clinical Trials
Due to supply chain issues and the need to build inventory, the first clinical trial treatments are now expected later in 2025, with the de novo submission anticipated in late 2026.
Company Guidance
During Vicarious Surgical's 2024 fourth quarter and full year earnings call, several key metrics and guidance were highlighted. The company reported total operating expenses for the full year at $66.6 million, down 17% year-over-year. Research and development expenses were $40.2 million, general and administrative expenses totaled $21.9 million, and sales and marketing expenses were $4.5 million. The adjusted net loss for 2024 was $63.3 million, equating to an adjusted net loss of $10.75 per share. Vicarious Surgical's cash burn rate for 2024 was $49 million, resulting in a year-end balance of $49 million in cash, cash equivalents, and short-term investments. Looking ahead, the company anticipates a cash burn of approximately $50 million in 2025, with plans to reinforce the balance sheet strategically. Additionally, their first clinical human trials are expected to commence closer to the end of the year, with a de novo submission anticipated for late 2026.Vicarious Surgical Corporate Events
Executive/Board Changes
Vicarious Surgical Appoints New Chief Financial Officer
Positive
Mar 13, 2025
On March 13, 2025, Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano, with over two decades of financial experience, is expected to leverage her expertise in financial strategy and corporate development to drive the company’s financial objectives and success, particularly as Vicarious Surgical approaches its first clinical use cases later this year.
Executive/Board Changes
Vicarious Surgical Announces COO Retirement in 2025
Neutral
Feb 18, 2025
On February 12, 2025, Vicarious Surgical announced the planned retirement of its Chief Operating Officer, John Mazzola, effective April 1, 2025. Mazzola, who has nearly 40 years of experience in healthcare manufacturing and quality control, has been pivotal in advancing the company’s manufacturing processes and supply chain resilience, positioning Vicarious Surgical for upcoming clinical use cases and trials. His responsibilities will transition to Randy Clark, the company’s President.
Executive/Board Changes
Vicarious Surgical Secures Advisory Role with Former CFO
Neutral
Jan 21, 2025
On January 17, 2025, Vicarious Surgical Inc. announced a consulting agreement with William Kelly following his departure as CFO. Mr. Kelly will provide advisory services until December 31, 2028, with compensation structured monthly and hourly, and his stock options will continue to vest until mid-2025, ensuring a smooth transition and maintaining company stability.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.